Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16731842 | 0.82 | NPSR1 (0.42) | CYP19A1CYP17A1NPSR1NAAAALDH1A1 | |
| SCHEMBL10891547 | 0.79 | NPSR1 (0.40) | CYP19A1CYP17A1NPSR1NAAAALDH1A1 | |
| SCHEMBL3125283 | 0.76 | NPSR1 (0.47) | CYP19A1CYP17A1NPSR1NAAAALDH1A1 | |
| SCHEMBL16731585 | 0.76 | CYP17A1 (0.50) | CYP19A1CYP17A1ALDH1A1HSD11B1 | |
| SCHEMBL16731576 | 0.76 | CYP17A1 (0.50) | CYP19A1CYP17A1ALDH1A1HSD11B1 | |
| SCHEMBL16731584 | 0.76 | CYP17A1 (0.50) | CYP19A1CYP17A1ALDH1A1HSD11B1 | |
| SCHEMBL865315 | 0.75 | NPSR1 (0.48) | CYP19A1CYP17A1NPSR1NAAAALDH1A1 | |
| SCHEMBL9608681 | 0.74 | CYP19A1 (0.50) | CYP19A1CYP17A1NPSR1NAAAALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28325233 | 0.74 | NPSR1 (0.45) | CYP19A1CYP17A1NPSR1NAAAALDH1A1 | |
| SCHEMBL11991228 | 0.72 | CYP19A1 (0.46) | CYP19A1CYP17A1NPSR1NAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428483-B2 | Prodrug of fluorine-containing amino acid | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-30 | — | — | US | disclosed |
| US-20150141669-A1 | PRODRUG OF FLUORINE-CONTAINING AMINO ACID | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141669-A1 | PRODRUG OF FLUORINE-CONTAINING AMINO ACID | SLC1A2, SLC1A1, SLC1A3 | CYP19A1 1910/4885CYP17A1 2604/4885NPSR1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.